Adult Cystic Fibrosis Pulmonology Clinical Trials

Study Title Description
CLAM320B2002M+A3: D9A3:D8
Multiple Patient Program for Lamprene (Clofazimine) for the Treatment of Non-TB Mycobacterial Infections
An expanded access of Lamprene (Clofazamine) to patients with Cystic Fibrosis patients with Mycobacterium infections
A Study to Evaluate EDP 938 Regimens in Infants With RSV (RSVPEDs)
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in infants with RSV infection. This is a randomized, double-blind, dose ranging, placebocontrolled study in respiratory syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to 24 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and antiviral activity of a 5 day treatment with EDP-938.
Prospective Study of Pregnancy in Women With Cystic Fibrosis
In this study, the investigators aim to evaluate changes in lung function in women with cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure to highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Vertex VX20-121-102 A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/DIVA) in CF participants who are heterozygous for F508del and a minimal function mutation (F/MF participants).
Vertex VX20-121-104 A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects with Cystic Fibrosis Who are Homozygous or Heterozygous for the F508del Mutation.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
AR-501 SAD and MAD of Inhaled AR501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects.  
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with chronic PsA pulmonary infection.
Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations